BRCA1 (Ab-1524) Antibody

What is the BRCA1 (Ab-1524) Antibody and what epitope does it recognize?

BRCA1 (Ab-1524) Antibody is a rabbit polyclonal antibody that specifically recognizes an epitope around amino acids 1522-1526 (Y-P-S-Q-E) of human BRCA1 protein. This antibody detects endogenous levels of total BRCA1 protein without requiring phosphorylation or other post-translational modifications at the recognition site. The antibody is generated by immunizing rabbits with a synthetic peptide-KLH conjugate and is subsequently purified via affinity chromatography using the epitope-specific peptide .

What are the validated applications for BRCA1 (Ab-1524) Antibody?

The BRCA1 (Ab-1524) Antibody has been validated for Western blotting (WB) and immunofluorescence (IF) applications with human samples. Experimental validation data demonstrates its efficacy in detecting BRCA1 in extracts from human cell lines including 293 and MCF cells. This antibody has not been validated for other applications such as immunoprecipitation, ChIP, or flow cytometry, so researchers should conduct preliminary validation if attempting these applications .

How should I optimize Western blot protocols when using BRCA1 (Ab-1524) Antibody?

When designing Western blot experiments with BRCA1 (Ab-1524) Antibody, consider the following optimization parameters:

These parameters should be further optimized based on your specific experimental conditions and cell types. The high molecular weight of BRCA1 (190-220 kDa) necessitates careful consideration of gel percentage and transfer conditions to ensure proper visualization of the target protein .

What controls should I include when using BRCA1 (Ab-1524) Antibody in my experiments?

For rigorous experimental design with BRCA1 (Ab-1524) Antibody, incorporate the following controls:

• Positive control: Lysates from cell lines known to express BRCA1 (e.g., MCF-7 or HEK293 cells)

• Negative control: Lysates from BRCA1-knockout cells or cells treated with BRCA1-specific siRNA

• Loading control: Detection of a housekeeping protein (e.g., β-actin, GAPDH) to normalize for loading variations

• Peptide competition: Pre-incubation of the antibody with the immunizing peptide to confirm specificity

• Secondary antibody only: Omission of primary antibody to identify non-specific binding of the secondary antibody

These controls help validate antibody specificity and ensure experimental reproducibility. For immunofluorescence experiments, include additional controls such as DAPI nuclear staining to correlate BRCA1 localization with nuclear structures .

How can I use BRCA1 (Ab-1524) Antibody to study DNA damage response pathways?

To investigate DNA damage response pathways using BRCA1 (Ab-1524) Antibody, implement the following methodological approach:

• Experimental setup: Treat cells with DNA-damaging agents (e.g., ionizing radiation, UV, cisplatin, or etoposide) at various dosages and time points.

• Protein extraction: Prepare nuclear and cytoplasmic fractions separately to track BRCA1 translocation.

• Western blot analysis: Use BRCA1 (Ab-1524) Antibody to detect total BRCA1 levels and distribution.

• Parallel phospho-specific detection: Combine with phospho-specific antibodies (e.g., phospho-S1423 or phospho-S1524) to monitor activation status.

• Immunofluorescence: Perform IF to visualize BRCA1 recruitment to DNA damage foci, co-staining with γ-H2AX or 53BP1 as damage markers.

• Co-immunoprecipitation: Assess BRCA1 interactions with BARD1, BRCA2, PALB2, or other DNA repair proteins.

This comprehensive approach allows for tracking both the expression levels and functional recruitment of BRCA1 to sites of DNA damage. The BRCA1 (Ab-1524) Antibody is particularly useful for establishing baseline BRCA1 levels against which phosphorylation-induced changes can be compared .

What immunofluorescence protocol yields optimal results with BRCA1 (Ab-1524) Antibody?

For optimal immunofluorescence results with BRCA1 (Ab-1524) Antibody, follow this refined protocol:

• Fixation: Fix cells with 4% paraformaldehyde for 15 minutes at room temperature.

• Permeabilization: Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes.

• Blocking: Block with 3% BSA in PBS for 1 hour at room temperature.

• Primary antibody: Dilute BRCA1 (Ab-1524) Antibody 1:50 to 1:100 in blocking solution; incubate overnight at 4°C.

• Washing: Wash 3 times with PBS, 5 minutes each.

• Secondary antibody: Apply fluorophore-conjugated anti-rabbit secondary antibody (e.g., FITC or Alexa Fluor) at 1:200-1:500 dilution for 1 hour at room temperature.

• Nuclear counterstain: Stain nuclei with DAPI (1 μg/ml) for 5 minutes.

• Mounting: Mount with anti-fade mounting medium.

Critical considerations include minimal exposure to light during and after secondary antibody application, and optimization of antibody concentration based on cell type. For formalin-fixed paraffin-embedded (FFPE) tissues, incorporate an antigen retrieval step (citrate buffer pH 6.0, 95°C for 20 minutes) before blocking .

How can I distinguish between phosphorylated and non-phosphorylated forms of BRCA1 in complex experimental systems?

Distinguishing between phosphorylated and non-phosphorylated BRCA1 forms requires a sophisticated experimental approach:

• Differential antibody strategy: Use BRCA1 (Ab-1524) Antibody to detect total BRCA1 alongside phospho-specific antibodies (e.g., phospho-S1423 or phospho-S1524) on parallel samples or sequential blots.

• Phosphatase treatment controls: Split your samples and treat one set with lambda phosphatase before immunoblotting to confirm phosphorylation-dependent signals.

• 2D gel electrophoresis: Separate proteins first by isoelectric point, then by molecular weight to resolve phospho-isoforms.

• Phos-tag™ SDS-PAGE: Incorporate Phos-tag™ in polyacrylamide gels to retard the migration of phosphorylated proteins, creating distinct bands for phosphorylated and non-phosphorylated forms.

• Mass spectrometry validation: Perform immunoprecipitation with BRCA1 (Ab-1524) Antibody followed by mass spectrometry to identify and quantify specific phosphorylation sites.

This multi-faceted approach enables comprehensive profiling of BRCA1 phosphorylation status in response to various experimental conditions. The specificity of the BRCA1 (Ab-1524) Antibody for total BRCA1 regardless of phosphorylation state makes it an ideal complement to phospho-specific antibodies in these analyses .

How does BRCA1 phosphorylation at S1524 differ from phosphorylation at other sites in terms of functional outcomes?

Phosphorylation of BRCA1 at different residues leads to distinct functional outcomes in DNA damage response:

When designing experiments to study these pathways, researchers should select specific DNA damaging agents that preferentially activate one kinase over others. For example, hydroxyurea or aphidicolin primarily activate ATR-dependent pathways and S1524 phosphorylation, while ionizing radiation primarily activates ATM-dependent pathways and S1423 phosphorylation. Using BRCA1 (Ab-1524) Antibody in combination with phospho-specific antibodies enables comprehensive analysis of how these different phosphorylation events coordinate BRCA1's multiple roles in DNA damage response .

What are the most common issues when using BRCA1 (Ab-1524) Antibody and how can they be resolved?

Researchers commonly encounter several challenges when working with BRCA1 (Ab-1524) Antibody:

• High molecular weight detection issues:

  • Problem: Faint or absent bands for BRCA1 (220 kDa)

  • Solution: Use gradient gels (4-12%), extend transfer time (overnight at 30V), and add 0.1% SDS to transfer buffer for large proteins

• Background noise in Western blots:

  • Problem: High background obscuring specific signals

  • Solution: Increase blocking time (2-3 hours), use 5% BSA instead of milk for blocking, and increase washing duration between antibody incubations

• Weak immunofluorescence signal:

  • Problem: Low signal intensity in IF applications

  • Solution: Optimize fixation (try 50:50 methanol:acetone instead of paraformaldehyde), increase antibody concentration (1:25 dilution), and extend primary antibody incubation to 48 hours at 4°C

• Inconsistent results between experiments:

  • Problem: Variable detection between replicates

  • Solution: Standardize lysate preparation (use phosphatase inhibitors and process samples immediately), maintain consistent freezing/thawing cycles, and prepare fresh antibody dilutions for each experiment

• Non-specific bands:

  • Problem: Detection of unexpected bands

  • Solution: Validate specificity using BRCA1 knockdown/knockout controls, perform peptide competition assays, and optimize antibody concentration (typically 1:1000-1:2000 for Western blots)

These methodological adjustments address the most common technical challenges encountered when working with this antibody for detection of this large, relatively low-abundance nuclear protein .

How can I optimize antibody conjugation for specialized applications?

For researchers requiring specialized applications beyond standard Western blotting and immunofluorescence, BRCA1 (Ab-1524) Antibody can be custom conjugated with various labels:

• Selection of appropriate conjugate:

  • For flow cytometry: Consider AF488, PE, or APC conjugates based on your instrument configuration

  • For multiplexed immunofluorescence: Choose spectrally distinct fluorophores (e.g., AF350, AF488, AF555, AF647)

  • For enzymatic detection: HRP or alkaline phosphatase conjugates provide amplified signal

• Conjugation protocol optimization:

  • Maintain antibody concentration at 1-2 mg/ml during conjugation

  • Use antibody-to-fluorophore ratios of 1:4 to 1:8 for optimal signal-to-noise

  • Purify conjugated antibody using size exclusion chromatography to remove unconjugated label

• Validation of conjugated antibody:

  • Compare staining patterns between unconjugated and conjugated antibody preparations

  • Determine optimal working concentration through titration experiments

  • Confirm retention of specificity using appropriate positive and negative controls

This methodological approach enables researchers to expand the utility of BRCA1 (Ab-1524) Antibody beyond its validated applications to specialized techniques including flow cytometry, high-content imaging, and multiplexed immunoassays .

How do I integrate BRCA1 antibody data with genetic analysis in translational research?

Integrating BRCA1 protein data (obtained using BRCA1 (Ab-1524) Antibody) with genetic analysis requires a carefully designed methodological approach:

• Coordinated sampling strategy:

  • Obtain matched samples for protein analysis and DNA sequencing

  • For patient-derived specimens, ensure adjacent sections for immunohistochemistry and genetic testing

  • For cell lines, maintain separate aliquots of the same passage for protein and DNA extraction

• Data integration methodology:

  • Correlate BRCA1 protein levels (quantified by Western blot) with genetic variants identified by sequencing

  • Categorize variants according to predicted impact (silent, missense, nonsense, frameshift)

  • Develop a scoring system combining protein expression level, localization pattern, and genetic status

• Statistical analysis framework:

  • Implement multivariate analysis to identify relationships between specific variants and protein expression/localization

  • Use clustering algorithms to identify patterns among variant-carrying samples

  • Conduct longitudinal analysis to track changes in BRCA1 expression during disease progression

• Validation strategy:

  • Confirm key findings using orthogonal methods (e.g., mass spectrometry for protein, digital PCR for genetic variants)

  • Establish cell models with specific BRCA1 variants using CRISPR-Cas9 to validate phenotypic effects

  • Correlate findings with clinical outcomes where applicable

This comprehensive approach allows researchers to establish meaningful connections between BRCA1 genetic alterations and their functional consequences at the protein level, providing insights relevant to cancer risk assessment and therapeutic response prediction .

How can I use BRCA1 (Ab-1524) Antibody to investigate the role of BRCA1 in non-canonical pathways beyond DNA repair?

While BRCA1 is primarily known for its role in DNA repair, it also functions in several non-canonical pathways that can be investigated using BRCA1 (Ab-1524) Antibody:

• Transcriptional regulation:

  • Perform ChIP assays using BRCA1 (Ab-1524) Antibody to identify genomic binding sites

  • Combine with RNA-seq after BRCA1 depletion to identify genes under BRCA1 transcriptional control

  • Use sequential ChIP to identify co-regulatory complexes containing BRCA1

• Metabolic regulation:

  • Investigate BRCA1 interaction with ACACA (acetyl-CoA carboxylase) using co-immunoprecipitation

  • Analyze lipid synthesis rates in relation to BRCA1 expression and localization

  • Compare metabolic profiles between BRCA1-proficient and BRCA1-deficient cells

• Centrosome regulation:

  • Use immunofluorescence to visualize BRCA1 localization at centrosomes during different cell cycle phases

  • Quantify centrosome number and microtubule nucleation in relation to BRCA1 status

  • Investigate interactions between BRCA1 and centrosomal proteins using proximity ligation assays

• Cell cycle checkpoints beyond DNA damage:

  • Monitor BRCA1 phosphorylation and localization during normal cell cycle progression

  • Investigate BRCA1 interactions with cell cycle regulators using immunoprecipitation

  • Analyze the impact of BRCA1 depletion on spindle assembly checkpoint function

These methodological approaches expand our understanding of BRCA1's multifaceted roles beyond canonical DNA repair functions. The BRCA1 (Ab-1524) Antibody's ability to detect total BRCA1 regardless of phosphorylation status makes it particularly valuable for these investigations, as various non-canonical functions may involve differently modified BRCA1 populations .

How can BRCA1 (Ab-1524) Antibody be used in PARP inhibitor response studies?

PARP inhibitors exploit synthetic lethality in BRCA1-deficient cells, making BRCA1 detection critical in related research. Here's a methodological framework for using BRCA1 (Ab-1524) Antibody in PARP inhibitor response studies:

• Baseline expression profiling:

  • Quantify BRCA1 protein levels across cell lines/patient samples using Western blotting

  • Correlate expression levels with known genetic status (wild-type, heterozygous, homozygous mutations)

  • Establish threshold BRCA1 levels associated with PARP inhibitor sensitivity

• Response monitoring protocol:

  • Track changes in BRCA1 expression during PARP inhibitor treatment

  • Monitor BRCA1 phosphorylation status (using phospho-specific antibodies alongside BRCA1 (Ab-1524) Antibody)

  • Assess nuclear vs. cytoplasmic distribution changes following treatment

• Resistance mechanism investigation:

  • Compare BRCA1 expression in sensitive vs. resistant cell populations

  • Evaluate BRCA1 expression in pre- and post-treatment patient samples

  • Analyze restoration of BRCA1 function through secondary mutations or alternative pathways

• Combination therapy assessment:

  • Examine BRCA1 expression changes during combination treatments

  • Identify synergistic drug combinations that modulate BRCA1 expression or localization

  • Develop biomarker signatures incorporating BRCA1 and related proteins

This systematic approach provides valuable insights into PARP inhibitor response mechanisms and may identify predictive biomarkers for clinical application. The ability of BRCA1 (Ab-1524) Antibody to detect total BRCA1 makes it particularly useful for establishing baseline expression levels across diverse samples .

What are the considerations for using BRCA1 (Ab-1524) Antibody in single-cell protein analysis techniques?

As single-cell analysis techniques gain prominence, adapting BRCA1 (Ab-1524) Antibody for these applications requires specific methodological considerations:

• Single-cell Western blotting:

  • Optimize cell lysis conditions to maintain protein integrity while ensuring complete extraction

  • Determine minimal detectable cell number (likely 50-100 cells minimum due to low BRCA1 abundance)

  • Implement signal amplification strategies (e.g., tyramide signal amplification) to enhance detection sensitivity

• Mass cytometry (CyTOF):

  • Conjugate BRCA1 (Ab-1524) Antibody with rare earth metals (e.g., lanthanides)

  • Validate metal-conjugated antibody using titration against known positive and negative controls

  • Combine with cell cycle markers to correlate BRCA1 expression with cell cycle phase

• Single-cell immunofluorescence:

  • Optimize fixation and permeabilization for individual cells in suspension

  • Implement image cytometry for quantitative analysis of BRCA1 levels and localization

  • Combine with DNA damage markers to assess correlation at single-cell resolution

• Microfluidic antibody capture:

  • Design capture chambers coated with anti-rabbit IgG for BRCA1 (Ab-1524) Antibody immobilization

  • Establish washing and elution protocols that maintain antibody activity

  • Integrate with downstream single-cell sequencing for combined protein-RNA analysis

These methodological adaptations enable researchers to explore cell-to-cell variation in BRCA1 expression and localization, potentially revealing subpopulations with distinct DNA repair capacities or drug sensitivities. The specificity of BRCA1 (Ab-1524) Antibody for total BRCA1 makes it valuable for establishing baseline heterogeneity in BRCA1 expression across cell populations .

How might advances in antibody technology impact future applications of BRCA1 detection?

Emerging antibody technologies will expand and refine BRCA1 detection capabilities beyond current applications of BRCA1 (Ab-1524) Antibody:

• Nanobody and single-domain antibody development:

  • Smaller size (15 kDa vs. 150 kDa) enables better tissue penetration

  • Potentially higher specificity for distinct BRCA1 conformational states

  • Enhanced performance in live-cell imaging applications

• Bi-specific antibody approaches:

  • Simultaneous detection of BRCA1 and interacting partners (e.g., BARD1, PALB2)

  • Direct visualization of protein complexes in situ

  • Quantification of specific BRCA1 complex formations in response to stimuli

• Advanced conjugation technologies:

  • Site-specific conjugation to maintain antigen-binding capacity

  • Quantum dot labeling for enhanced photostability in long-term imaging

  • Click chemistry approaches for modular labeling strategies

• Intracellular antibody delivery systems:

  • Liposomal or nanoparticle-based delivery of antibodies to living cells

  • Cell-penetrating peptide conjugation for enhanced cellular uptake

  • Direct expression of intrabodies for real-time BRCA1 monitoring